Mind Cure Health Inc. (MCURF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mind Cure Health Inc. (MCURF) trades at $0.51 with AI Score 44/100 (Grade C). Mind Cure Health Inc. focuses on developing digital therapeutics and researching psychedelic compounds for mental health and wellness. Market cap: $86.53M, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for MCURF: MCURF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MCURF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MCURF: the 1 perspectives are evenly split.
How is this calculated? →Mind Cure Health Inc. (MCURF) Healthcare & Pipeline Overview
Mind Cure Health Inc., a life sciences company, develops and commercializes mental health and wellness products in North America, focusing on digital therapeutics and psychedelic compound research. Their iSTRYM platform and PsyCollage bioinformatics tools aim to optimize mental health therapy and research, positioning them in the evolving biotechnology sector.
What Is the Investment Thesis for MCURF?
Mind Cure Health Inc. presents a speculative investment thesis centered on its development of digital therapeutics and psychedelic compound research. The company's iSTRYM platform and PsyCollage bioinformatics tool represent potential value drivers in the mental health therapy space. However, the company's negative P/E ratio of -4.61 and OTC market listing indicate substantial risk. Growth catalysts include successful clinical trials and regulatory approvals for its psychedelic compounds, as well as increased adoption of its iSTRYM platform. The company's success hinges on navigating the regulatory landscape, securing funding, and demonstrating clinical efficacy.
Based on FMP financials and quantitative analysis
MCURF Key Highlights
- Market capitalization of $86.53M reflects the company's small size and early stage in the biotechnology sector.
- Negative P/E ratio of -4.61 indicates that the company is currently not profitable, typical for early-stage biotech companies investing heavily in research and development.
- Beta of -0.26 suggests the stock price is less volatile than the overall market, which may appeal to risk-averse investors but also indicates limited potential for rapid gains.
- The company's focus on digital therapeutics and psychedelic compounds aligns with emerging trends in mental health treatment.
- Listing on the OTC market presents both opportunities and risks, including lower liquidity and less stringent regulatory requirements compared to major exchanges.
Who Are MCURF's Competitors?
MCURF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADOIF Adocia S.A. | $8.87 | +0.00% | $103.66M | 52 |
| BSTG Biostage, Inc. | $4.03 | +0.75% | $57.82M | 44 |
| CKMTF Carmat S.A. | $12.75 | -50.96% | $85.19M | 61 |
| EPRXF Eupraxia Pharmaceuticals Inc. | $3.04 | -6.17% | $108.29M | 44 |
| ETXPF E-therapeutics Plc | $0.13 | +0.00% | $75.96M | 38 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MCURF's Key Strengths?
- Innovative digital therapeutics platform (iSTRYM).
- Focus on psychedelic compound research.
- Bioinformatics platform (PsyCollage) for research.
- Early mover advantage in the emerging psychedelic therapy market.
What Are MCURF's Weaknesses?
- Limited operating history as a relatively new company (incorporated in 2020).
- Negative P/E ratio indicating lack of profitability.
- Reliance on regulatory approvals for psychedelic compounds.
- Limited financial resources compared to larger pharmaceutical companies.
What Could Drive MCURF Stock Higher?
- Clinical trial results for psychedelic compounds targeting traumatic brain injuries.
- Regulatory approvals for iSTRYM platform in key markets.
- Expansion of iSTRYM platform capabilities and user base.
- Strategic partnerships with research institutions and pharmaceutical companies.
- Development of new digital therapeutics solutions.
What Are the Key Risks for MCURF?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Stringent regulatory requirements for psychedelic compounds.
- Competition from established pharmaceutical companies and other emerging biotech firms.
- Negative clinical trial results for psychedelic compounds.
- Limited financial resources and reliance on external funding.
- Fluctuations in market sentiment towards psychedelic therapies.
What Are the Growth Opportunities for MCURF?
- Expansion of iSTRYM Platform: The iSTRYM digital therapeutics platform represents a significant growth opportunity for Mind Cure Health. By expanding the platform's capabilities and integrating it with various mental health therapies, the company can attract a larger user base of clinicians and patients. The market for digital therapeutics is projected to reach $9.6 billion by 2028, offering substantial revenue potential. Successful implementation and positive user feedback will be crucial for driving adoption and market penetration.
- Advancement of Psychedelic Compound Research: Mind Cure Health's research into psychedelic compounds, including ibogaine, for traumatic brain injuries and related conditions presents a high-potential growth avenue. Positive results from clinical trials could lead to regulatory approvals and commercialization opportunities. The market for psychedelic therapies is estimated to reach $10.75 billion by 2027. Securing patents and demonstrating clinical efficacy are key to capitalizing on this opportunity.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with research institutions, pharmaceutical companies, and mental health clinics can accelerate Mind Cure Health's growth. Collaborations can provide access to resources, expertise, and distribution channels. For example, partnering with a major hospital network could facilitate the integration of iSTRYM into clinical practice. Successful partnerships can enhance the company's credibility and market reach.
- Geographic Expansion into New Markets: Expanding operations beyond North America into Europe and other regions represents a significant growth opportunity. The global market for mental health treatments is substantial, and Mind Cure Health's digital therapeutics and psychedelic research could appeal to international markets. Adapting products and services to meet local regulatory requirements and cultural preferences will be essential for successful expansion.
- Development of New Digital Therapeutics Solutions: Investing in the development of new digital therapeutics solutions beyond iSTRYM can drive future growth. This could include apps for specific mental health conditions, virtual reality therapies, or AI-powered diagnostic tools. The digital health market is rapidly evolving, and continuous innovation is crucial for maintaining a competitive edge. Successful product development can attract new customers and generate additional revenue streams.
What Opportunities Does MCURF Have?
- Growing market for mental health treatments.
- Increasing acceptance of psychedelic-assisted therapies.
- Potential for strategic partnerships and collaborations.
- Expansion into new geographic markets.
What Threats Does MCURF Face?
- Stringent regulatory requirements for psychedelic compounds.
- Competition from established pharmaceutical companies.
- Potential for negative clinical trial results.
- Fluctuations in market sentiment towards psychedelic therapies.
What Are MCURF's Competitive Advantages?
- Proprietary digital therapeutics platform (iSTRYM).
- Research and development in psychedelic compounds.
- Bioinformatics platform (PsyCollage) for research.
- Focus on specific mental health conditions like traumatic brain injuries.
What Does MCURF Do?
Mind Cure Health Inc. was incorporated in 2020 and is headquartered in Vancouver, Canada. The company operates as a life sciences entity focused on developing and commercializing mental health and wellness products in North America. Mind Cure Health's core mission revolves around leveraging digital therapeutics technology and researching psychedelic compounds to rapidly scale science-backed and evidence-based mental health therapy. Their key product is iSTRYM, a digital therapeutics tool designed to optimize the healing journey for patients and clinicians before, during, and after therapy sessions. Additionally, the company has developed PsyCollage, a bioinformatics platform intended to drive research by identifying priority research programs. Mind Cure Health also focuses on the research and potential supply of synthetic ibogaine to researchers and clinicians, as well as other psychedelic compounds, including ibogaine for traumatic brain injuries and related conditions. The company is positioning itself to be a leader in the evolving mental health treatment landscape, emphasizing technology and research-driven solutions.
What Products and Services Does MCURF Offer?
- Develop digital therapeutics tools for mental health.
- Research psychedelic compounds for therapeutic applications.
- Create software applications to optimize mental health therapy.
- Develop bioinformatics platforms to drive research programs.
- Focus on treatments for traumatic brain injuries and related conditions.
- Commercialize mental health and wellness products in North America.
How Does MCURF Make Money?
- Develop and license digital therapeutics platforms like iSTRYM.
- Conduct research and development on psychedelic compounds.
- Potentially supply synthetic ibogaine to researchers and clinicians.
- Commercialize mental health and wellness products.
What Industry Does MCURF Operate In?
Mind Cure Health Inc. operates within the rapidly evolving biotechnology industry, specifically targeting the mental health and wellness sector. The industry is witnessing a surge in interest in psychedelic-assisted therapies and digital therapeutics. Companies like Atai Life Sciences and Compass Pathways are also exploring psychedelic compounds for mental health treatments. The market is driven by increasing awareness of mental health issues and a growing demand for innovative treatment options. Mind Cure Health's focus on digital tools and research positions it to capitalize on these trends, but it faces competition from established pharmaceutical companies and other emerging biotech firms.
Who Are MCURF's Key Customers?
- Mental health clinicians and therapists.
- Patients seeking mental health treatment.
- Research institutions studying psychedelic compounds.
- Pharmaceutical companies interested in licensing digital therapeutics.
Key Financial Metrics
Its free cash flow yield is -8.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.76 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -20.9%, the inverse of the P/E and a quick read on earnings relative to price.
How Mind Cure Health Inc. Is Valued
Mind Cure Health Inc. carries a market capitalization of $86.53M, placing it in the micro-cap category. Relative to its peer group, MCURF's quantitative score of 44/100 is roughly in line with the peer average of 48/100.
F-Score 2/9Financial Health
Mind Cure Health Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
MCURF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Mind Cure's future prospects, indicating executives believe in the company's potential.
- Community sentiment has shifted positively, with discussions highlighting the innovative approaches Mind Cure is taking in the mental health sector.
- The growing awareness and acceptance of mental health treatments can boost demand for Mind Cure's offerings, positioning them well in a burgeoning market.
- Recent partnerships and collaborations have been viewed favorably, suggesting a strategic alignment that could enhance their market presence.
Bear Case
- Concerns persist regarding the regulatory landscape surrounding mental health treatments, which could pose challenges for Mind Cure's growth.
- Some community members express skepticism about the scalability of Mind Cure's products, fearing they may not achieve widespread adoption.
- Recent market sentiment has been mixed, with bearish views highlighting potential competition that could hinder Mind Cure's market share.
- The company's financial health remains a topic of debate, with some analysts questioning sustainability in the face of ongoing operational costs.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
MCURF Latest News
No recent news available for MCURF.
MCURF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MCURF.
Price Targets
Wall Street price target analysis for MCURF.
MCURF MoonshotScore
What does this score mean?
The MoonshotScore rates MCURF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Pablo Navarro
CEO
Pablo Navarro serves as the Chief Executive Officer of Mind Cure Health Inc. His background includes experience in the healthcare and life sciences sectors, with a focus on strategic leadership and business development. He has a track record of driving growth and innovation in emerging companies. Navarro's expertise lies in identifying market opportunities, building strong teams, and executing strategic plans to achieve corporate objectives. His leadership is focused on advancing Mind Cure Health's mission of developing innovative mental health solutions.
Track Record: Since assuming the role of CEO, Pablo Navarro has focused on advancing Mind Cure Health's digital therapeutics platform and psychedelic compound research. Key milestones under his leadership include the development and launch of the iSTRYM platform and the initiation of clinical trials for psychedelic compounds. He has also focused on securing funding and building strategic partnerships to support the company's growth initiatives. His leadership is aimed at positioning Mind Cure Health as a leader in the mental health treatment landscape.
MCURF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Mind Cure Health Inc. may not meet the minimum financial standards or reporting requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries a higher degree of risk compared to those listed on major exchanges like the NYSE or NASDAQ due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Lower liquidity compared to major exchanges.
- Higher potential for price volatility.
- Increased risk of fraud or manipulation.
- Limited regulatory oversight and investor protection.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Check for any legal or regulatory issues.
- Monitor the company's news and press releases.
- Consult with a financial advisor.
- Company's focus on developing digital therapeutics and researching psychedelic compounds.
- Development of the iSTRYM platform and PsyCollage bioinformatics tool.
- Presence of a CEO with experience in the healthcare and life sciences sectors.
- Company's stated mission to develop innovative mental health solutions.
- Listing on the OTC market, even at the 'Other' tier, indicates some level of public presence.
Mind Cure Health Inc. Healthcare Stock: Key Questions Answered
What does Mind Cure Health Inc. do?
Mind Cure Health Inc. is a life sciences company focused on developing and commercializing mental health and wellness products in North America. The company's core business revolves around two main areas: digital therapeutics and psychedelic compound research. Their iSTRYM platform is a digital tool designed to optimize mental health therapy, while their research efforts focus on psychedelic compounds like ibogaine for treating conditions such as traumatic brain injuries. The company aims to provide science-backed and evidence-based mental health solutions.
What do analysts say about MCURF stock?
Given MCURF's OTC listing and small market capitalization, formal analyst coverage may be limited. However, potential investors should focus on key valuation metrics such as revenue growth, cash burn rate, and progress in clinical trials. The company's growth prospects hinge on the successful development and commercialization of its digital therapeutics platform and psychedelic compounds. Investors should carefully assess the risks associated with investing in an early-stage biotech company operating in a highly regulated industry.
What are the main risks for MCURF?
Mind Cure Health Inc. faces several key risks, including regulatory hurdles for psychedelic compounds, competition from larger pharmaceutical companies, and the potential for negative clinical trial results. The company's limited financial resources and reliance on external funding also pose a risk. Additionally, fluctuations in market sentiment towards psychedelic therapies and the inherent uncertainty of drug development could impact the company's prospects. Investing in MCURF involves a high degree of risk due to its early stage and the speculative nature of the psychedelic therapy market.
What are the key factors to evaluate for MCURF?
Mind Cure Health Inc. (MCURF) holds an AI score of 44/100 (low). Not financial advice.
How frequently does MCURF data refresh on this page?
MCURF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven MCURF's recent stock price performance?
Mind Cure Health Inc. (MCURF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative digital therapeutics platform (iSTRYM). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MCURF overvalued or undervalued right now?
Valuing Mind Cure Health Inc. (MCURF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying MCURF?
Before investing in Mind Cure Health Inc. (MCURF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be subject to change.
- OTC market data may be less reliable than major exchange data.
- AI analysis is pending and may provide further insights.